Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine

Pain

Volumn 142, Issue 3, 2009, Pages 225-235

  Desaphy, Jean François ^a   Dipalma, Antonella ^a   De Bellis, Michela ^a   Costanza, Teresa ^a   Gaudioso, Christelle ^b   Delmas, Patrick ^b   George Jr , Alfred L ^c   Camerino, Diana Conte ^a  

^a Dipartimento di Geologia e Geofisica   (Italy)

^b University of Mediterranée   (France)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Analgesia; DRG sensory neurons; Local anesthetic; Orphenadrine; Sodium channel subtypes; Toxic effects

Indexed keywords

FLECAINIDE; LOCAL ANESTHETIC AGENT; MEXILETINE; ORPHENADRINE; TETRODOTOXIN; VOLTAGE GATED SODIUM CHANNEL;

ANALGESIA; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; MALE; NOCICEPTION; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; SENSORY NERVE CELL; SITE DIRECTED MUTAGENESIS; SODIUM CURRENT; SPINAL GANGLION; WHOLE CELL;

ANALGESICS; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GANGLIA, SPINAL; ION CHANNEL GATING; MALE; MEMBRANE POTENTIALS; NEURONS; ORPHENADRINE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHANNELS;

EID: 61849100988     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2009.01.010     Document Type: Article

References (50)

1. Akopian A.N., Souslova V., England S., Okuse K., Ogata N., Ure J., Smith A., Kerr B.J., McMahon S.B., and Boyce S. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 2 (1999) 541-548
2. Bean B.P., Cohen C.J., and Tsien R.W. Lidocaine block of cardiac sodium channels. J Gen Physiol 81 (1983) 613-642
3. Black J.A., Liu S., Tanaka M., Cummins T.R., and Waxman S.G. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 108 (2004) 237-247
4. Catterall W.A., Perez-Reyes E., Snutch T.P., and Striessnig J. International Union of Pharmacology XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 57 (2005) 411-425
5. Chahine M., Bennett P.B., George Jr. A.L., and Horn R. Functional expression and properties of the human skeletal muscle sodium channel. Pflügers Arch 427 (1994) 136-142
6. Chou R., Peterson K., and Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 28 (2004) 140-175
7. 2+ currents, and mechanically activated cation currents in different populations of DRG neurons. J Gen Physiol 129 (2007) 57-77
8. Coste B., Osorio F., Padilla F., Crest M., and Delmas P. Gating and modulation of presumptive NaV1.9 channels in enteric and spinal sensory neurons. Mol Cell Neurosci 26 (2004) 123-134
9. Cox J.J., Reimann F., and Nicholas A.K. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444 (2006) 894-898
10. Cummins T.R., Sheets P.L., and Waxman S.G. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain 131 (2007) 243-257
11. Danze L.K., and Langdorf M.I. Reversal of orphenadrine-induced ventricular tachycardia with physostigmine. J Emerg Med 9 (1991) 453-457
12. Desaphy J.-F., De Luca A., Tortorella P., De Vito D., George Jr. A.L., and Conte Camerino D. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 57 (2001) 1849-1857
13. Desaphy J.-F., De Luca A., Didonna M.P., George Jr. A.L., and Conte Camerino D. Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block. J Physiol 554 (2004) 321-334
14. Devor M., Wall P.D., and Catalan N. Systemic lidocaine silences ectopic neuroma and DRG discharge without blocking nerve conduction. Pain 48 (1992) 261-268
15. Drenth J.P., and Waxman S.G. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest 117 (2007) 3603-3609
16. Elmalem J., Garnier R., Nguyen Huu Chieu R., Bismuth C., and Efthymiou M.L. Acute poisoning by orphenadrine. Ann Med Interne (Paris) 136 (1985) 640-645
17. Fernández-Sánchez M.T., Díaz-Trelles R., Groppetti A., Manfredi B., Brini A.T., Biella G., Sotgiu M.L., and Novelli A. Nefopam, an analogue of orphenadrine, protects against both NMDA receptor-dependent and independent veratridine-induced neurotoxicity. Amino Acids 23 (2002) 31-36
18. Gjerden P., Engelstad K.S., Pettersen G., and Slordal L. Fatalities caused by anticholinergic antiparkinsonian drugs. Analysis of findings in a 11-year national material. Tidsskr Nor Laegeforen 118 (1998) 42-44 Norwegian
19. Gold R.H. Treatment of low back syndrome with oral orphenadrine citrate. Curr Ther Res 23 (1978) 271-276
20. Hille B. Local anesthetic: hydrophilic and hydrophobic pathways for the drug receptor reaction. J Gen Physiol 69 (1977) 497-515
21. Hunskaar S., and Donnell D. Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions. J Int Med Res 19 (1991) 71-87
22. Kim Y.S., Shin Y.K., Lee C., and Song J. Block of sodium currents in rat dorsal root ganglion neurons by diphenhydramine. Brain Res 881 (2000) 190-198
23. Klugbauer N., Lacinova L., Flockerzi V., and Hofmann F. Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J 14 (1995) 1084-1090
24. Kornhuber J., Parsons C.G., Hartmann S., Kamolz S., Thome J., and Riederer P. Orphenadrine is an uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J Neural Trans Gen Sect 2 (1995) 237-246
25. + current by diphenhydramine and other diphenyl compounds: molecular determinants of selective binding to the inactivated channels. Mol Pharmacol 57 (2000) 135-143
26. Labout J.J.M., Thijssen C.T., Keijser G.G.J., and Hespe W. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. Eur J Clin Pharmacol 21 (1982) 343-350
27. Lai J., Hunter J.C., and Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr Opin Neurobiol 13 (2003) 291-297
28. Lee S.Y., Oh H.J., Kim J.W., Kim Y.G., Moon C.J., and Lee E.H. Pharmacokinetic study of orphenadrine using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). J Chromatogr B Anal Technol Biomed Life Sci 839 (2006) 118-123
29. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 22 (2005) 731-740
30. Legroux-Crespel E., Sassolas B., Guillet G., Kupfer I., Drupe D., and Misery L. Treatment of familial erythermalgia with the association of lidocaine and mexiletine. Ann Dermatol Venereol 130 (2003) 429-433
31. Lossin C., Wang D.W., Rhodes T.H., Vanoye C.G., and George Jr. A.L. Molecular basis of an inherited epilepsy. Neuron 34 (2002) 877-884
32. Luzza F., Raffa S., Saporito F., and Oreto G. Torsades de pointes in congenital long QT syndrome following low-dose orphenadrine. Int J Clin Pract 60 (2006) 606-608
33. Maingret F., Coste B., Padilla F., Clerc N., Crest M., Korogod S.M., and Delmas P. Inflammatory mediators increase Nav1.9 current and excitability in nociceptors through a coincident detection mechanism. J Gen Physiol 131 (2008) 211-225
34. Maruyama H., Nakamoto M., Matsunomi T., Zheng T., Nakata Y., Wood J.N., and Ogata N. Electrophysiological characterization of the tetrodotoxin-resistant Na+ channel, Nav(1.9), in mouse dorsal root ganglion neurons. Pflugers Arch 449 (2004) 76-87
35. Priest B.T., Murphy B.A., Lindia J.A., Diaz C., Abbadie C., Ritter A.M., Liberator P., Iyer L.M., Kash S.F., Kohler M.G., Kaczorowski G.J., MacIntyre D.E., and Martin W.J. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel Nav1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci USA 102 (2005) 9382-9387
36. Priest B.T., and Kaczorowski G.J. Blocking sodium channels to treat neuropathic pain. Exp Opin Ther Targets 11 (2007) 291-306
37. Pubill D., Canudas A.M., Pallàs M., Sureda F.X., Escubedo E., Camins A., and Camarasa J. Assessment of the adrenergic effects of orphenadrine in rat vas deferens. J Pharm Pharmacol 51 (1999) 307-312
38. Pullen G.P., Best N.R., and Maguire J. Anticholinergic drug abuse: a common problem?. Br Med J 289 (1984) 612-613
39. Ragsdale D.S., McPhee J.C., Scheuer T., and Catterall W.A. Molecular determinants of state-dependent block of Na channels by local anesthetic. Science 265 (1994) 1724-1728
40. Roza C., Laird J.M., Souslova V., Wood J.N., and Cervero F. The tetrodotoxin-resistant Na+ channel Nav1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J Physiol 550 (2003) 921-926
41. Rumore M.M., and Schlichting D.A. Analgesic effects of antihistaminics. Life Sci 36 (1985) 403-416
42. Schaffler K., and Reitmeir P. Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia. A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory-evoked potentials obtained from capsaicin-irritated skin in healthy volunteers. Arzneimittelforschung 54 (2004) 673-679
43. Scholz E.P., Konrad M.F., Weiss D.L., Zitron E., Kiesecker C., Bloehs R., Kulzer M., Thomas D., Kathofer S., Bauer A., Maurer M.H., Seemann G., Katus H.A., and Karle C.A. Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656. Naunyn-Schmiedeberg's Arch Pharmacol 376 (2007) 275-284
44. Standaert D.G., and Young A.B. Treatment of central nervous system degenerative disorders. In: Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., and Goodman Gilman A. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. (1995), McGraw-Hill, New York 503-519
45. Sweeney P.J. Parkinson's disease: managing symptoms and preserving function. Geriatrics 509 (1995) 24-31
46. Syvälahti E.K., Kunelius R., and Laurén L. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol 62 (1988) 90-94
47. Taglialatela M., Timmerman H., and Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 21 (2000) 52-56
48. Wang D.W., George Jr. A.L., and Bennett P.B. Comparison of heterologously expressed human cardiac and skeletal muscle sodium channels. Biophys J 70 (1996) 238-245
49. Waxman S.G. Nav1.7, its mutations, and the syndromes that they cause. Neurology 69 (2007) 505-507
50. Wright S.N., Wang S.Y., Kallen R.G., and Wang G.K. Differences in steady-state inactivation between Na channel isoforms affect local anesthetic binding affinity. Biophys J 73 (1997) 779-788